percutaneous myocardial revascularization

Also found in: Dictionary, Acronyms.

percutaneous myocardial revascularization

Percutaneous transluminal myocardial revascularization, see there.


(re'vas?kyu-la-ri-za'shon) [ re- + vascularization]
Restoration of blood flow to an organ. This may be done surgically or by removing or dissolving thrombi occluding arteries, esp. coronary or renal arteries.

cerebral revascularization

The surgical restoration of blood flow to the brain, e.g., with an operation to bypass a blockage in the carotid or cerebral arteries.

hybrid coronary artery revascularization

An invasive treatment for multivessel coronary artery disease in which the patient undergoes both minimally invasive direct coronary artery bypass of the left anterior descending artery and stent placement into the right coronary artery or the circumflex artery.

percutaneous myocardial revascularization

Transmyocardial revascularization.

transmyocardial revascularization

Abbreviation: TMR
The use of a laser to bore tiny channels directly through the wall of the heart in an attempt to bring oxygen-rich blood from the left ventricular cavity to areas where the heart muscle is oxygen-deprived, or ischemic. TMR is an alternative to coronary bypass surgery or angioplasty, esp. in patients with complex plaques that would be difficult to reach with standard interventions or in patients who have already undergone many other procedures without effect.
Synonym: percutaneous myocardial revascularization
References in periodicals archive ?
In regards to Percutaneous Myocardial Revascularization being included on the agenda for the meeting, Quinn said that the Company had not requested any such review of PMR at this time and is requesting clarification from CMS regarding that topic.
CardioGenesis Corporation (BULLETIN BOARD: CGCP) , the worldwide leader in angina- relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Revascularization (PMR), announced that it will release its financial results for the first quarter ended March 31, 2004, before the market opens on Wednesday, May 5, 2004.
CardioGenesis Corporation (BULLETIN BOARD: CGCP) , the worldwide leader in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Revascularization (PMR), today announced that new, conclusive five-year data demonstrates the enduring benefits of TMR when performed on patients with diffuse coronary disease in conjunction with coronary bypass artery grafting (CABG) surgery.

Medical browser ?
Full browser ?